Cancer Patients Flock to China’s Hainan for Experimental Drug Trials
On the sun-soaked southern tip of China, a new kind of medical tourism is quietly unfolding. It’s not about cosmetic surgery or wellness spas but about survival.
Scientists in Australia and the U.S. have developed an AI tool that could transform cancer care by revealing the hidden diversity of tumour cells and guiding more targeted therapies.
A team of Australian and American researchers has unveiled a powerful new artificial intelligence (AI) tool designed to decode the complex biology of tumours and improve cancer treatment outcomes. The innovation addresses tumour heterogeneity—variations among cancer cells within the same tumour—that has long hindered the effectiveness of standard therapies.
Developed jointly by Sydney’s Garvan Institute of Medical Research and the Yale School of Medicine, the tool, known as AAnet, uses deep learning to analyse gene activity at the single-cell level. According to the researchers, AAnet can distinguish five distinct cell types within a tumour, each with unique behaviours and potential to spread, offering far more precision than traditional diagnostic methods.
“Heterogeneity is a problem because currently we treat tumours as if they are made up of the same cell,” said Associate Professor Christine Chaffer from the Garvan Institute, who co-led the study. “This means we give one therapy that kills most cells in the tumour by targeting a particular mechanism. But not all cancer cells may share that mechanism.”
By identifying the biological traits of different cancer cell populations, AAnet allows clinicians to tailor combination therapies that target all types of tumour cells at once, potentially reducing treatment resistance and relapse.
Co-developer Associate Professor Smita Krishnaswamy of Yale University described AAnet as the first tool capable of simplifying the complexity of tumour cells into actionable categories. She said it could pave the way for a new era of precision oncology where treatments are personalised to the unique cellular makeup of each patient’s tumour.
Validated initially in breast cancer, AAnet has also shown promise for other cancer types and even autoimmune diseases. The team plans to integrate AI insights with conventional diagnostics in clinical settings, offering personalised treatment plans based on the specific cell types within each tumour.
The findings were published in the journal Cancer Discovery, marking a significant step toward more effective, individualised cancer care.
Iran launched 18 ballistic missiles late Sunday targeting the U.S. military’s Al-Udeid Air Base in Qatar, the largest American installation in the Middle East.
Iranian missiles struck multiple locations across Israel and neighbouring regions early Friday morning, including a Microsoft office complex, according to emergency responders and local media reports.
A high-speed tram derailment in central Gothenburg, Sweden, has left at least eight people injured late on Thursday (19 June), after the vehicle slammed into a snack bar on Avenyn Avenue.
Wizz Air has suspended all flights to and from Tel Aviv, Israel, and its European services to Amman, Jordan, effective immediately until 15 September due to escalating situation in the Middle East. Also, the air carrier temporarily suspended its flights between Astana, Kazakhstan, and Abu Dhabi.
China has unveiled a mosquito-sized bionic drone designed for covert military operations and battlefield reconnaissance, marking a major advance in micro-robotics and stealth technology as part of the country’s growing focus on next-generation warfare capabilities.
Singapore has launched its largest-ever study on paediatric food allergies, aiming to better understand and address the growing burden of allergic reactions among children.
Bill Gates says his foundation will not compensate for funding shortfalls caused by U.S. and UK aid cuts to global vaccination efforts, warning of rising child mortality as a result.
The world is facing a health financing emergency as global health investment risks falling to its lowest level in a decade, the World Health Organization (WHO) warned.
China has successfully mastered the technology to produce Yttrium-90, a critical medical isotope used in radiation therapy for liver cancer, within a commercial nuclear reactor.
German biotech firm BioNTech (22UAy.DE), has agreed to acquire domestic peer CureVac, for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment